FDA withdraws Covid antibody treatment Evusheld because it's not effective against 93% of subvariants
Publishing timestamp: 2023-01-26 23:37:04
Summary
The FDA pulled AstraZeneca's Evusheld, an antibody injection that people with weak immune systems relied on for additional protection against Covid-19, from the market because it is not effective against more than 90% of Covid subvariants that are currently circulating in U.S. There is currently no replacement for Evusheld and President Joe Biden has urged people with compromised immune systems to consult with their doctors on the right steps to protect themselves.
Sentiment: NEGATIVE
Keywords: pandemics, business, astrazeneca plc, breaking news: business, epidemics, joe biden, coronavirus, biotechnology, u.s. economy, business news, biotech and pharmaceuticals, politics, disease outbreaks, health care industry,